Unmet Needs and Clinical Data with Hepatic Artery Infusion in Intrahepatic Cholangiocarcinoma

Opinion
Video

Drs Connell and Merkow discuss the current treatment landscape in intrahepatic cholangiocarcinoma and review recent clinical data in that space.

Related Videos
Jonathan E. Rosenberg, MD
Michael Iglesia, MD, PhD
Nan Chen, MD
Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video 9 - "Additional Second-Line Treatments for HCC"
Jin Qian, PhD
A panel of 4 experts on colorectal cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Michael Iglesia, MD, PhD
Related Content
Timothy L. Cannon, MD

Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer

May 15th 2024
Article
Ryan Merkow, MD, MS, associate professor, surgery, director, Surgical Cancer Quality, associate director, Health Services Research, Department of Surgery, director, Hepatic Artery Infusion Pump Program, University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line; Louise Catherine Connell, MB BCh BAO, BMedSc, assistant attending physician, Memorial Sloan Kettering Cancer Center

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

May 2nd 2024
Podcast
Susanna Hegewisch-Becker, MD, PhD

Relatlimab Plus Nivolumab/Chemo Misses ORR End Point in LAG-3+ Advanced Gastric/GEJ Cancer

May 14th 2024
Article
Saad Z. Usmani, MD, MBA, FACP, FASCO, hematologist-oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

April 22nd 2024
Podcast
Gastric cancer | Image Credit: © Rasi - stock.adobe.com

IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer

May 8th 2024
Article
US FDA

FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer

May 8th 2024
Article